MTEM - Molecular Templates, Inc. Company Total Debt

The Molecular Templates (MTEM) price chart reflects debt dynamics, which currently stand at 0.01. Molecular Templates owns its own cGMP facility in Texas, ensuring the autonomy of biopharmaceutical supplies. However, high development complexity and capital requirements create significant risks. The business is currently shifting its model, cutting loss-making projects to preserve capital and commercialize its patents.

Molecular Templates Corporation - MTEM Company Debts (period 07/04/2022 - 12/28/2024)

Financial and market metric breakdowns for Molecular Templates, Inc. (MTEM)

- price and consensus price forecast:

Share Price Molecular Templates Corporation|MTEM - Analyst Consensus Forecast

- market capitalization data:

Market Valuation Molecular Templates Corp|MTEM - Total Company Value

- book capitalization data:

Net Asset Value per Share Molecular Templates|MTEM - Company Book Value|Market Value to Book Value Ratio mtem.com|MTEM - Aggregate Company Assets

- debt and liquidity data:

Debt to Capital Molecular Templates|MTEM - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Molecular Templates Inc|MTEM - Company Total Debt|Debts to Book Value Molecular Templates Corp|MTEM - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Molecular Templates

Fundamental company valuation:MTEM (Molecular Templates Corporation)

Signature product of Molecular Templates, Inc.

As a biotechnology company with capital-intensive R&D expenditures for laboratories, Molecular Templates utilizes debt capital to scale its targeted therapy platform. The current value of 0.01 reflects the total volume of liabilities, where the dynamics of the company's obligations allow for an assessment of the balance between liquidity shortage risk and the efficiency of credit leverage for developing universal tumor treatment methods.

Main competitors